Nektar Therapeutics reported one‑year follow‑up data showing rezpegaldesleukin sustained and in some cases deepened skin‑clearance responses in patients with moderate‑to‑severe atopic dermatitis. Both monthly and quarterly maintenance dosing preserved high EASI responses, with the company highlighting less‑frequent dosing as a potential competitive edge versus established biologics. Nektar said the Phase 2 maintenance results support its planned Phase 3 design and an FDA submission timeline targeting 2029 if later trials confirm the effect. Investors reacted positively, reflecting broader market appetite for long‑acting immunomodulators that could reduce treatment burden.